An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
about
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationProinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.IGF-IR promotes prostate cancer growth by stabilizing α5β1 integrin protein levelsEnhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial CellsCrosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis.Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.Up-regulation of integrin α6β4 expression by mitogens involved in dairy cow mammary development.Direct binding to integrins and loss of disulfide linkage in interleukin-1β (IL-1β) are involved in the agonistic action of IL-1β.Mechano growth factor E peptide inhibits invasion of melanoma cells and up-regulates CHOP expression via endoplasmic reticulum stress.Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner.
P2860
Q34387886-99C66832-A5D7-4867-A595-90053E650C7CQ34801388-23D3F025-F294-48FD-A906-A81ECC2D6EE6Q35018529-64275C24-6C07-4BFA-9911-AAE8C3F40274Q35763007-32563D9A-A5AF-4767-BA6E-D2AC180FCC61Q39132510-EEAF857C-B891-4C7D-A8A2-F1F1300C9B33Q41059246-119EB340-DF54-4BC2-B244-8311CE1D9B4AQ41617811-320F2C6F-9669-4085-B7D3-4DB2518D0C98Q42467236-4A3218C5-2D6C-4A89-9546-622FF65847D8Q46979263-6C87F2C1-4EE4-4D2D-94D7-92104484DA48Q47684477-D0DFF14E-4FD0-48C5-8DDC-C5BB0B58AD41Q51316539-8779CDFD-3E47-4F73-A493-782A6D8053EC
P2860
An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An integrin binding-defective ...... esis but still binds to IGF1R.
@en
An integrin binding-defective mutant of insulin-like growth factor-1
@nl
type
label
An integrin binding-defective ...... esis but still binds to IGF1R.
@en
An integrin binding-defective mutant of insulin-like growth factor-1
@nl
prefLabel
An integrin binding-defective ...... esis but still binds to IGF1R.
@en
An integrin binding-defective mutant of insulin-like growth factor-1
@nl
P2093
P2860
P356
P1476
An integrin binding-defective ...... esis but still binds to IGF1R.
@en
P2093
Alexander D Borowsky
Andrew Fong
Anthony T W Cheung
Charles Wilkerson
Dora M Cedano-Prieto
Jane Q Chen
Katsuaki Ieguchi
Masaaki Fujita
Robert D Cardiff
P2860
P304
19593-19603
P356
10.1074/JBC.M113.470872
P407
P577
2013-05-21T00:00:00Z